JP7743312B2 - Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 - Google Patents

Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法

Info

Publication number
JP7743312B2
JP7743312B2 JP2021568893A JP2021568893A JP7743312B2 JP 7743312 B2 JP7743312 B2 JP 7743312B2 JP 2021568893 A JP2021568893 A JP 2021568893A JP 2021568893 A JP2021568893 A JP 2021568893A JP 7743312 B2 JP7743312 B2 JP 7743312B2
Authority
JP
Japan
Prior art keywords
group
antibody
alkyl
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021568893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532918A (ja
JP2022532918A5 (https=
Inventor
ティー． バーガー，マシュー
チャンリオン，マイア
コランド，フレデリック
セケイ，マートン
ドゥラクール，レア
デソス，パトリース
ジュネステ，オリビエ
ヘンリン，ジャン－ミッシェル
コストバ，ヴェセラ
コチュヒ，アンドラス
マラグノ，アナ，レティシア
マクニール，エリック
パレルモ，マーク，ジー．
ロケッティ，フランセスカ
スターク，ジェローム
ユ，ビン
ジャン，チャン
プロスゼンヤク，アグネス
シポス，サボルクス
アンソニー ダレシオ，ジョセフ
勝正 中嶋
チェン，ジュオリャン
Original Assignee
ノバルティス アーゲー
レス ラボラトイレス セルビエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, レス ラボラトイレス セルビエル filed Critical ノバルティス アーゲー
Publication of JP2022532918A publication Critical patent/JP2022532918A/ja
Publication of JP2022532918A5 publication Critical patent/JP2022532918A5/ja
Priority to JP2025150534A priority Critical patent/JP2025183333A/ja
Application granted granted Critical
Publication of JP7743312B2 publication Critical patent/JP7743312B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021568893A 2019-05-20 2020-05-19 Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 Active JP7743312B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025150534A JP2025183333A (ja) 2019-05-20 2025-09-10 Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962850098P 2019-05-20 2019-05-20
US62/850,098 2019-05-20
PCT/US2020/033615 WO2020236825A2 (en) 2019-05-20 2020-05-19 Mcl-1 inhibitor antibody-drug conjugates and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025150534A Division JP2025183333A (ja) 2019-05-20 2025-09-10 Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法

Publications (3)

Publication Number Publication Date
JP2022532918A JP2022532918A (ja) 2022-07-20
JP2022532918A5 JP2022532918A5 (https=) 2023-07-13
JP7743312B2 true JP7743312B2 (ja) 2025-09-24

Family

ID=70978687

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021568893A Active JP7743312B2 (ja) 2019-05-20 2020-05-19 Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
JP2021568870A Active JP7663514B2 (ja) 2019-05-20 2020-05-19 Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
JP2025150534A Pending JP2025183333A (ja) 2019-05-20 2025-09-10 Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021568870A Active JP7663514B2 (ja) 2019-05-20 2020-05-19 Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
JP2025150534A Pending JP2025183333A (ja) 2019-05-20 2025-09-10 Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法

Country Status (23)

Country Link
US (2) US20230092679A1 (https=)
EP (2) EP3972649A2 (https=)
JP (3) JP7743312B2 (https=)
KR (2) KR20220024106A (https=)
CN (2) CN114728077A (https=)
AR (1) AR122270A1 (https=)
AU (2) AU2020279230A1 (https=)
BR (1) BR112021023229A2 (https=)
CA (2) CA3136088A1 (https=)
CL (1) CL2021003042A1 (https=)
CO (1) CO2021016552A2 (https=)
DO (1) DOP2021000238A (https=)
GE (2) GEP20257822B (https=)
IL (2) IL288110A (https=)
JO (1) JOP20210289A1 (https=)
MX (1) MX2021014094A (https=)
PE (1) PE20220218A1 (https=)
PH (1) PH12021552831A1 (https=)
PY (1) PY2020118A (https=)
SG (1) SG11202112056PA (https=)
TW (1) TW202100184A (https=)
UY (1) UY38700A (https=)
WO (2) WO2020236825A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087580A4 (en) * 2020-01-07 2024-01-17 Purdue Research Foundation TARGETED STEROID COMPOUNDS
SI4153242T1 (sl) * 2020-05-19 2024-07-31 Les Laboratoires Servier Para-amino-benzilni linkerji, postopek za njihovo pripravo in njihova uporaba v konjugatih
WO2022093800A2 (en) 2020-10-27 2022-05-05 Elucida Oncology, Inc. Carrier particle-drug conjugates, self-immolative linkers, and uses thereof
AU2021386367A1 (en) 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
IL303079A (en) * 2020-11-24 2023-07-01 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
WO2022266491A1 (en) * 2021-06-18 2022-12-22 University Of Maryland, Baltimore Proteolysis targeting chimeras and polypharmacological agents targeting bcl-2, and methods of use thereof
US20230212181A1 (en) * 2022-01-01 2023-07-06 Aarvik Therapeutics, Inc. Double payload cancer therapeutics
US20260061065A1 (en) 2022-05-20 2026-03-05 Novartis Ag Antibody drug conjugates
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
AU2023279443A1 (en) * 2022-06-03 2025-01-23 Ube Corporation Antibody-multidrug conjugate
WO2023234427A1 (ja) * 2022-06-03 2023-12-07 Ｕｂｅ株式会社 抗体・複数薬物コンジュゲート前駆体およびその合成中間体
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN120475995A (zh) * 2022-08-17 2025-08-12 隆萨销售股份有限公司 包含生物活性分子和可裂解接头的细胞外囊泡
WO2024040075A1 (en) * 2022-08-17 2024-02-22 Lonza Sales Ag Extracellular vesicle comprising a biologically active molecule and a dual cleavable linker
KR20250080903A (ko) * 2022-10-19 2025-06-05 멀티튜드 테라퓨틱스 인코퍼레이티드 항체-약물 접합체, 이의 제조 방법 및 용도
EP4710944A1 (en) * 2023-05-09 2026-03-18 Shanghai Henlius Biotech, Inc. Anti-pdl1 antibody-drug conjugate and use
CN121263211A (zh) * 2023-05-09 2026-01-02 上海复宏汉霖生物技术股份有限公司 一种抗表皮生长因子受体(egfr)抗体-药物偶联物及其应用
CN117229190A (zh) * 2023-06-06 2023-12-15 武汉翱飞科技有限公司 一种马来酰亚胺型连接子及其制备方法与应用
TW202523328A (zh) * 2023-11-17 2025-06-16 美商建南德克公司 Ｍｃｌ－１抑制劑化合物及在抗體藥物結合物中之用途
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015129120A (ja) 2013-12-23 2015-07-16 レ ラボラトワール セルヴィエ 新規なチエノピリミジン誘導体、その製造方法及びそれを含有する医薬組成物
JP2016512832A (ja) 2013-03-15 2016-05-09 ノバルティス アーゲー 抗体薬物コンジュゲート
JP2016518332A (ja) 2013-03-13 2016-06-23 ノバルティス アーゲー 抗体薬物コンジュゲート
JP2018527296A (ja) 2015-06-23 2018-09-20 レ ラボラトワール セルヴィエ 新規なヒドロキシ酸誘導体、その製造方法、及びそれを含有する医薬組成物
JP2019511559A (ja) 2016-01-19 2019-04-25 レ ラボラトワール セルヴィエ 新規アンモニウム誘導体、それを調製するためのプロセス及びそれを含有する医薬組成物

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7312318B2 (en) * 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2855520B1 (en) 2012-06-04 2018-09-26 Novartis AG Site-specific labeling methods and molecules produced thereby
US20140069822A1 (en) 2012-09-10 2014-03-13 Antec Leyden B.V. Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction
ES2732574T3 (es) 2012-11-30 2019-11-25 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
EP2953976B1 (en) 2013-02-08 2021-03-24 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
ES2671516T3 (es) 2013-02-19 2018-06-06 Novartis Ag Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015095227A2 (en) * 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
JP2017509337A (ja) 2014-03-12 2017-04-06 ノバルティス アーゲー イムノコンジュゲートを作製する抗体を修飾するための特定部位
SG11201607339VA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
TW201625692A (zh) * 2014-11-14 2016-07-16 諾華公司 抗體藥物結合物
CN111620861A (zh) 2014-12-09 2020-09-04 艾伯维公司 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物
CN113209306A (zh) 2014-12-09 2021-08-06 艾伯维公司 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物
CN107207553A (zh) 2014-12-09 2017-09-26 艾伯维公司 Bcl‑xl抑制性化合物和包括其的抗体药物缀合物
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3165536A1 (en) * 2015-11-09 2017-05-10 Ludwig-Maximilians-Universität München Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
US11306107B2 (en) 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein
ES2791319T3 (es) 2016-04-22 2020-11-03 Astrazeneca Ab Inhibidores de MCL1 macrocíclicos para tratar el cáncer
BR112018075639A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. conjugados de anticorpo fármaco anti-egfr
WO2017214462A2 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
AU2017279550A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
AU2017277534A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-EGFR antibody drug conjugates
RU2018147224A (ru) 2016-06-08 2020-07-14 Эббви Инк. Конъюгаты антитела к egfr и лекарственного средства
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
RU2019114863A (ru) * 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
CA3043277A1 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
WO2018098534A1 (en) * 2016-12-02 2018-06-07 Garvan Institute Of Medical Research Methods of treating cancer and reagents thereof
CN110461361A (zh) * 2017-02-10 2019-11-15 蜻蜓治疗公司 结合bcma、nkg2d和cd16的蛋白
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
WO2018192407A1 (zh) * 2017-04-19 2018-10-25 四川科伦博泰生物医药股份有限公司 细胞毒素和偶联物、其用途和制备方法
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
MA51447A (fr) * 2017-08-01 2020-06-10 Medimmune Llc Conjugué anticorps monoclonal-médicament dirigé contre bcma
AU2018317828A1 (en) 2017-08-15 2020-04-02 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
US10676485B2 (en) 2017-08-15 2020-06-09 Abbvie Inc. Macrocyclic MCL-1 inhibitors and methods of use
TW201920193A (zh) 2017-08-15 2019-06-01 美商艾伯維有限公司 大環ｍｅｌ-１抑制劑以及使用方法
US20190160089A1 (en) * 2017-10-31 2019-05-30 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
MX2020012674A (es) * 2018-05-29 2021-02-09 Bristol Myers Squibb Co Porciones autoinmolantes modificadas para usarse en profarmacos y conjugados y metodos de uso y fabricacion.
EP3807644A4 (en) * 2018-06-12 2022-07-06 Angiex, Inc. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518332A (ja) 2013-03-13 2016-06-23 ノバルティス アーゲー 抗体薬物コンジュゲート
JP2016512832A (ja) 2013-03-15 2016-05-09 ノバルティス アーゲー 抗体薬物コンジュゲート
JP2015129120A (ja) 2013-12-23 2015-07-16 レ ラボラトワール セルヴィエ 新規なチエノピリミジン誘導体、その製造方法及びそれを含有する医薬組成物
JP2018527296A (ja) 2015-06-23 2018-09-20 レ ラボラトワール セルヴィエ 新規なヒドロキシ酸誘導体、その製造方法、及びそれを含有する医薬組成物
JP2019511559A (ja) 2016-01-19 2019-04-25 レ ラボラトワール セルヴィエ 新規アンモニウム誘導体、それを調製するためのプロセス及びそれを含有する医薬組成物

Also Published As

Publication number Publication date
IL288110A (en) 2022-01-01
BR112021023229A2 (pt) 2022-05-31
JP2025183333A (ja) 2025-12-16
WO2020236825A8 (en) 2021-03-18
GEP20257822B (en) 2025-11-10
PE20220218A1 (es) 2022-02-02
DOP2021000238A (es) 2022-03-31
PY2020118A (es) 2022-10-27
UY38700A (es) 2020-12-31
KR20220024106A (ko) 2022-03-03
CL2021003042A1 (es) 2022-07-15
US20230092679A1 (en) 2023-03-23
AU2020279979A1 (en) 2021-11-25
WO2020236817A8 (en) 2021-05-20
WO2020236817A3 (en) 2020-12-30
CN114728076A (zh) 2022-07-08
AR122270A1 (es) 2022-08-31
JP7663514B2 (ja) 2025-04-16
CA3136088A1 (en) 2020-11-26
EP3972651A2 (en) 2022-03-30
SG11202112056PA (en) 2021-12-30
JP2022532918A (ja) 2022-07-20
WO2020236817A2 (en) 2020-11-26
CO2021016552A2 (es) 2022-04-08
TW202100184A (zh) 2021-01-01
JOP20210289A1 (ar) 2023-01-30
EP3972649A2 (en) 2022-03-30
CN114728077A (zh) 2022-07-08
CA3138058A1 (en) 2020-11-26
MX2021014094A (es) 2022-02-11
WO2020236825A2 (en) 2020-11-26
JP2022533400A (ja) 2022-07-22
GEAP202515825A (en) 2025-07-25
WO2020236825A3 (en) 2021-02-18
US20230081720A1 (en) 2023-03-16
AU2020279230A1 (en) 2021-12-02
KR20220017931A (ko) 2022-02-14
PH12021552831A1 (en) 2023-01-16
IL288117A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
JP7743312B2 (ja) Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
US20240042051A1 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP2023553811A (ja) Ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用方法
EP4525926A1 (en) Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
RU2854591C2 (ru) Конъюгаты антитело-лекарственное средство ингибитора MCL-1 и способы их применения
RU2849608C2 (ru) Конъюгаты антитело-лекарственное средство ингибитора mcl-1 и способы их применения
EA052397B1 (ru) КОНЪЮГАТЫ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО ИНГИБИТОРА Mcl-1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK40077041A (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP2025517430A (ja) Ｅｐｈａ２ ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用の方法
HK40077285A (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
OA21037A (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250812

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250910

R150 Certificate of patent or registration of utility model

Ref document number: 7743312

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150